NKG2D CAR-NK Cell Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Latest Information Update: 18 Jan 2023
At a glance
- Drugs Anti-NKG2D chimeric antigen receptor natural killer cell therapy-Hangzhou Cheetah Cell Therapeutics (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors Hangzhou Cheetah Cell Therapeutics
Most Recent Events
- 11 Jan 2023 Status changed from recruiting to discontinued.
- 24 Feb 2022 New trial record